Form 4: Guardant Health Executive Reports Stock Transactions

Guardant Health's Chief Legal Officer, John G. Saia, reported transactions involving the acquisition of common stock and restricted stock units.

Summary

• John G. Saia, Chief Legal Officer of Guardant Health, Inc., reported several transactions on July 1, 2026.
• These transactions include the acquisition of common stock through the vesting of restricted stock units.
• A total of 974 shares were acquired, bringing the total beneficial ownership to 37,409 shares.
• An additional 1,667 shares were acquired, increasing beneficial ownership to 39,076 shares.
• Another 2,925 shares were acquired, raising beneficial ownership to 42,001 shares.
• Furthermore, 1,497 shares were acquired, resulting in a total beneficial ownership of 43,498 shares.
• In a separate transaction, 3,707 shares were disposed of at a price of $170.77 per share, reducing beneficial ownership to 39,791 shares.
• The filing also details the acquisition of restricted stock units, with 974 units granted on November 7, 2022, vesting over four years.
• Additionally, 1,667 restricted stock units were granted on December 13, 2023, vesting over three years.
• Another 2,925 restricted stock units were granted on November 8, 2024, vesting over three years.
• Finally, 1,497 restricted stock units were granted on March 12, 2025, vesting over three years.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the disposal of shares by a key executive, although the acquisition of shares through RSUs provides a counterbalancing positive signal.

Positives

• Acquisition of common stock through the vesting of restricted stock units indicates continued equity participation by a key executive.
• The executive's beneficial ownership of a significant number of shares (39,791 after the reported transactions) suggests alignment with shareholder interests.

Negatives

• The disposal of 3,707 shares at $170.77 per share could indicate a decision by the executive to reduce their holdings, potentially signaling a less optimistic short-term outlook or a need for liquidity.

Risks

• The disposal of shares by a key executive could be interpreted negatively by the market, although the reason for the sale is not specified.
• The vesting schedules of restricted stock units indicate future potential dilution if these units are exercised and converted into common stock.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the ongoing vesting of restricted stock units implies future share issuances.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported activity by Guardant Health's Chief Legal Officer is typical for executives managing their equity compensation and personal investment portfolios. The specific details of the transactions, including the disposal of shares, will be closely watched by investors for any potential implications regarding management's confidence in the company's future performance.

Stakeholder Impact

• Shareholders: The disposal of shares by an executive may influence investor sentiment. The ongoing vesting of RSUs represents potential future dilution.
• Employees: The executive's transactions do not directly impact other employees, but reflect the company's equity compensation practices.
• Management: The transactions reflect the management of executive compensation and personal investment strategies.

Next Steps

• Continued monitoring of John G. Saia's beneficial ownership and any future transactions.
• Observation of the vesting schedules for the reported restricted stock units.

Key Dates

Recommendation

The filing reports routine insider transactions, including the acquisition of stock through restricted stock units and the disposal of shares. While the disposal of shares by a key executive can be a negative signal, the overall context of equity compensation and the executive retaining a significant beneficial ownership suggests a 'hold' recommendation. Further analysis of the company's financial performance and strategic outlook would be necessary for a stronger recommendation.

Keywords

Guardant Health, GH, Form 4, SEC Filing, Insider Trading, Stock Transaction, Restricted Stock Units, Beneficial Ownership, John G. Saia, Chief Legal Officer